Since its discovery in 1998, RNA interference (RNAi) has become a key tool in functional genomics. By delivering synthetic siRNA to degrade target mRNA, it enables rapid, specific, and reversible gene silencing—widely used in tumor immunology, inflammation, and metabolic disease research.
Yet siRNA transfection remains challenging:
- Primary cells are fragile and hard to transfect;
- Immune and suspension cells resist nucleic acid uptake due to unique or complex membrane properties;
- Differentiated cells often fail with conventional reagents.
- These limitations lead to low knockdown efficiency, high variability, or cell death—creating a major bottleneck in RNAi experiments.
Figure 1. Schematic of the siRNA-mediated RNA interference pathway
I. Yeasen RNAiBoost – A Lipid Nanoparticle Breakthrough for siRNA Delivery
After 10 years of R&D, Yeasen developed RNAiBoost (Cat. No. 40807ES)—a next-generation siRNA transfection reagent that overcomes the limitations of traditional liposomes.
Core Technology: Next-Generation Lipid Nanoparticle (LNP) Delivery Platform
Unlike conventional liposomes, RNAiBoost uses a tailored lipid nanoparticle (LNP) system with three key advantages:
- Strong Membrane Perturbation – Overcoming Endocytosis Barriers
Traditional liposomes show low fusion efficiency in immune and primary cells. RNAiBoost employs novel lipid nanoparticles with enhanced membrane-perturbing capability, promoting efficient membrane fusion and endocytosis—dramatically improving cellular uptake across difficult-to-transfect cell types, including adherent, immune, and suspension cells.
- Endosomal Escape Technology – Solving the “Last Mile” Problem
After internalization, siRNA is often trapped and degraded in endosomes. RNAiBoost’s cationic lipid nanoparticles feature pH-sensitive membrane disruption: upon endosomal acidification, they induce membrane rupture or pore formation, enabling efficient cytosolic release of functional siRNA—completing the journey from “cell entry” to “gene silencing.”
- Ultra-High Cellular Utilization – Less Is More
RNAiBoost’s exceptional intracellular utilization sets it apart from leading global reagents:
More siRNA reaches its target with less input—achieving >90% knockdown at low doses (5–50 nM), minimal toxicity, and no need for media change.
|
Comparison Criteria |
Conventional Transfection Reagents |
Yeasen-RNAiBoost |
|
siRNA Concentration |
High dose (20–100 nM) |
Low dose (5–50 nM) |
|
Cellular Uptake |
Large amount enters cells, but most is degraded |
Precise delivery with efficient utilization |
|
Functional siRNA Reaching Cytoplasm |
Low |
High |
|
Target Gene Knockdown Efficiency |
Moderate (50–70%) |
Outstanding (>90%) |
|
Post-Transfection Cell Viability |
~70% |
>90% |
|
Cytotoxicity |
Moderate |
Low |
|
Medium Change Required |
Yes |
No |
II. Hard Data: How RNAiBoost Conquers the “Transfection Black Hole”
Leveraging the comprehensive advantages of lipid nanoparticle (LNP) technology, RNAiBoost delivers exceptional performance across a wide range of challenging cell types, consistently outperforming mainstream international siRNA transfection reagents in both knockdown efficiency and cell viability.
Performance Across Diverse Cell Models
|
Cell Type |
Cell Category |
RNAiBoost Knockdown Efficiency |
Cell Viability |
|
BMDM |
Primary macrophages |
>95% |
>95% |
|
RAW264.7 |
Mouse macrophage cell line |
>95% |
>95% |
|
THP-1 & Induced Macrophages |
Human monocytic cell line (Suspension) |
>80% |
>95% |
|
HUVEC |
Primary endothelial cells |
>90% |
>95% |
|
HepG2 |
Human hepatocellular carcinoma cells |
>95% |
>95% |
|
MCF |
Mouse cardiac fibroblasts |
>80% |
>95% |
|
STC-1 |
Mouse intestinal endocrine cells |
>95% |
>95% |
|
LX-2 |
Human hepatic stellate cells |
>90% |
>95% |
|
BEAS-2B |
Human normal lung epithelial cells |
>85% |
>95% |
|
HK-2 |
Human renal proximal tubular epithelial cells |
>90% |
>95% |
In-Depth Case Studies
Cas 1. Primary Cells
|
BMDM cell |
|
|
|
|
Cas 2. Hard-to-Transfect Cell Lines-RAW264.7, MCF, STC-1, LX-2, HepG2, BEAS-2B, HK-2
|
RAW264.7 |
|
|
|
|
|
STC 1 |
LX-2 |
|
|
|
|
HepG2 |
BEAS-2B |
|
|
|
|
HK2 |
|
|
|
|
Cas 3. Immune & Suspension Cells-THP-1/M0
Related Products
|
Name |
Size |
Cat.NO. |
|
100 μL/0.75 mL/1.5 mL |
40807ES01/03/04 |
|
|
100 μL/0.75 mL/1.5 mL |
40801ES01/03/04 |
Try it for free!
Get a free sample of Hieff Trans™ Booster and validate its performance in your own lab.
👉 [Request Sample Now]